Optimal Timing for Oral Anticoagulant Discontinuation and Prognosis after Successful Catheter Ablation for Atrial Fibrillation (JCEP July 2026)-Article: Optimal Timing for Oral Anticoagulant Discontinuation and Prognosis after Successful Catheter Ablation for Atrial Fibrillation

Article: Optimal Timing for Oral Anticoagulant Discontinuation and Prognosis after Successful Catheter Ablation for Atrial Fibrillation

Back to course

Pdf Summary

This retrospective single-center study examined 2,448 patients who underwent first catheter ablation for atrial fibrillation between 2006 and 2022 to determine the best time to stop oral anticoagulants (OACs) after successful ablation. Using 537 landmark time points and inverse probability weighting, the authors compared thromboembolic, bleeding, and mortality outcomes between patients who discontinued OACs and those who continued them.<br /><br />During a median follow-up of 34.1 months, thromboembolic events occurred in 2.7% of patients and major bleeding in 2.5%. The risk of thromboembolism after OAC discontinuation rose early, around 4–5 months after ablation, while bleeding risk gradually decreased the longer OACs were continued. A “reverse net clinical benefit” analysis identified 8.1 months after ablation as the point where the balance of benefits and harms was most favorable for stopping OACs.<br /><br />At the 8.1-month landmark, stopping OACs was linked to higher thromboembolic risk but lower bleeding risk, with no significant difference in all-cause mortality. Specifically, OAC discontinuation was associated with reduced major bleeding and intracranial hemorrhage, but increased thromboembolism compared with continued therapy. Subgroup analyses suggested extra caution for patients with asymptomatic atrial fibrillation or left ventricular ejection fraction ≤60%, who had higher thromboembolic risk after discontinuation. Patients with higher HAS-BLED scores appeared to benefit more from stopping OACs because of bleeding reduction.<br /><br />Overall, the study suggests that OAC discontinuation around 8.1 months after successful atrial fibrillation ablation may offer the best trade-off between stroke prevention and bleeding risk, though decisions should be individualized based on patient risk profile and rhythm monitoring.

Meta Tag

Concept Oral Anticoagulant

Concept Catheter Ablation

Concept Atrial Fibrillation

Concept Anticoagulant Discontinuation

Concept Thrombosis Risk

Keywords

atrial fibrillation

catheter ablation

oral anticoagulants

OAC discontinuation

thromboembolic risk

major bleeding

intracranial hemorrhage

net clinical benefit

HAS-BLED score

stroke prevention

Oral Anticoagulant

Catheter Ablation

Atrial Fibrillation

Anticoagulant Discontinuation

Thrombosis Risk